| [1] |
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications[J]. Nat Rev Endocrinol, 2018, 14(2):88-98.
|
| [2] |
国家老年医学中心，中华医学会老年医学分会，中国老年保健协会糖尿病专业委员会.中国老年糖尿病诊疗指南（2024版）[J].中华糖尿病杂志，2024,16(2):147-189.
|
| [3] |
Leley SP, Ciulla TA, Bhatwadekar AD. Diabetic retinopathy in the aging population: A perspective of pathogenesis and treatment[J]. Clin Interv Aging, 2021, 16:1367-1378.
|
| [4] |
中华医学会糖尿病学分会视网膜病变学组.糖尿病相关眼病防治多学科中国专家共识(2021版)[J].中华糖尿病杂志，2021,13(11):1026-1042.
|
| [5] |
中华医学会眼科学分会眼底病学组，中国医师协会眼科医师分会眼底病学组.我国糖尿病视网膜病变临床诊疗指南（2022年）——基于循证医学修订[J].中华眼底病杂志，2023,39(2):91-94.
|
| [6] |
Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications[J]. Redox Biol, 2020, 37:101799.
|
| [7] |
Sadikan MZ, Abdul Nasir NA, Bakar NS, et al. Tocotrienol-rich fraction reduces retinal inflammation and angiogenesis in rats with streptozotocin-induced diabetes[J]. BMC Complement Med Ther, 2023, 23(1):179.
|
| [8] |
陈铭豪，刘沛雨，王旋，等.糖尿病视网膜病变的药物治疗研究进展[J].上海交通大学学报（医学版），2024,44(7):822-829.
|
| [9] |
Keane PA, Sadda SR. Development of anti-VEGF therapies for intraocular use: A guide for clinicians[J]. J Ophthalmol, 2012, 2012:483034.
|
| [10] |
Kholodenko RV, Kalinovsky DV, Doronin II, et al. Antibody fragments as potential biopharmaceuticals for cancer therapy: success and limitations[J]. Curr Med Chem, 2019, 26(3):396-426.
|
| [11] |
Tietz J, Spohn G, Schmid G, et al. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor a for the treatment of retinal disorders[J]. Invest Ophthalmol Vis Sci, 2015, 56(7):3.
|
| [12] |
Tadayoni R, Sararols L, Weissgerber G, et al. Brolucizumab: A newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration[J]. Ophthalmologica, 2021, 244(2):93-101.
|
| [13] |
Escher D, Schmidt A, Steiner P, et al. Single-chain antibody fragments in ophthalmology[G]. Nice: the European Society of Retina Specialists (EURETINA), 2015.
|
| [14] |
Bates A, Power CA, David VS. Goliath: the structure, function, and clinical prospects of antibody fragments[J]. Antibodies (Basel), 2019, 8(2):28.
|
| [15] |
Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration[J]. Ophthalmology, 2020, 127(1):72-84.
|
| [16] |
Joo K, Park SJ, Choi Y, et al. Role of the Fc region in the vitreous half-life of anti-VEGF drugs[J]. Invest Ophthalmol Vis Sci, 2017, 58(10):4261-4267.
|
| [17] |
Jain A, Jain SK. PEGylation: an approach for drug delivery. A review[J]. Crit Rev Ther Drug Carrier Syst, 2008, 25(5):403-447.
|
| [18] |
Müller D, Karle A, Meissburger B, et al. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin[J]. J Biol Chem, 2007, 282(17):12650-12660.
|
| [19] |
Fogli S, Del RM, Rofi E, et al. Clinical pharmacology of intravitreal anti-VEGF drugs[J]. Eye (Lond), 2018, 32(6):1010-1020.
|
| [20] |
Garcia-Quintanilla L, Luaces-Rodríguez A, Gil-Martínez M, et al. Pharmacokinetics of intravitreal anti-VEGF drugs in age related macular degeneration[J]. Pharmaceutics, 2019, 11:365-387.
|
| [21] |
Montoliu-Gaya L, Esquerda-Canals G, Bronsoms S, et al. Production of an anti-Aβ antibody fragment in pichia pastoris and in vitro and in vivo validation of its therapeutic effect[J]. PLoS One, 2017, 12(8):e0181480.
|
| [22] |
Spadiut O, Capone S, Krainer F, et al. Microbials for the production of monoclonal antibodies and antibody fragments[J]. Trends Biotechnol, 2014, 32(1):54-60.
|
| [23] |
Sharma A, Kumar N, Kuppermann BD, et al. Brolucizimab-leading an era of structural revolution for long-term VEGF suppression[J]. Eye (Lond), 2020, 34(4):611-613.
|
| [24] |
Brown DM, Emanuelli A, Bandello F, et al. KESTREL and KITE: 52-week results from two phase Ⅲ pivotal trials of brolucizumab for diabetic macular edema[J]. Am J Ophthalmol, 2022, 238:157-172.
|
| [25] |
Bilgic A, Kodjikian L, March de Ribot F, et al. Real-world experience with brolucizumab in wet age-related macular degeneration: the REBA study[J]. J Clin Med, 2021, 10(13):2758.
|
| [26] |
Bilgic A, Kodjikian L, de Ribot FM, et al. Real-world experience with brolucizumab in neovascular age-related macular degeneration over 2 years: the REBA extension study[J]. Graefes Arch Clin Exp Ophthalmol, 2024, 262(4):1161-1167.
|
| [27] |
Coney JM, Zubricky R, Sinha SB, et al. Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration[J]. Int J Retina Vitreous, 2023, 9(1):8.
|
| [28] |
Yongsoo K, Wykoff CC, Emanuelli A, et al. Brolucizumab for the treatment of proliferative diabetic retinopathy: 54-week results from the CONDOR study[G]. Washington: the Association For Research In Vision And Ophthalmology (ARVO), 2024.
|
| [29] |
Mishra SK, Kumar P, Joshi A, et al. Efficacy & safety of brolucizumab 6.0 mg versus 3.6 mg in diabetic macular edema[J]. Int J Retina Vitreous, 2025, 11(1):6.
|
| [30] |
Chakraborty S, Sheth JU, Campa C. Contralateral effect following intravitreal brolucizumab injection in diabetic macular edema[J]. Case Rep Ophthalmol Med, 2022, 2022:1-4.
|
| [31] |
Mahapatra SK, Das A. Initial experience in off-label use of brolucizumab in diabetic macular edema and retinal vein occlusion[J]. Curr Indian Eye Res J Ophthalmic Res Group, 2021, 54(49):51.
|
| [32] |
Beretta F, Zucchiatti I, Sacconi R, et al. Two-years real-world experience of a tertiary center with intravitreal brolucizumab switch for treatment of exudative neovascular age-related macular degeneration[J]. Ophthalmol Ther, doi: 10.1007/s40123-025-01141-y. Epub 2025 Apr 18.
|
| [33] |
Singh RP, Barakat MR, Ip MS, et al. Efficacy and safety of brolucizumab for diabetic macular edema: the KINGFISHER randomized clinical trial[J]. JAMA Ophthalmol, 2023, 141(12):1152-1160.
|
| [34] |
Wykoff CC, Garweg JG, Regillo C, et al. KESTREL and KITE phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema[J]. Am J Ophthalmol, 2024, 260:70-83.
|
| [35] |
Liang K, Gui S, Wang X, et al. Association of diabetic retinopathy on all-cause and cause-specific mortality in older adults with diabetes: National Health and Nutrition Examination Survey, 2005-2008[J]. Sci Rep, 2024, 14(1):10458.
|
| [36] |
Canada's Drug and Health Technology Agency. SR0719-000 Faricimab (Vabysmo) 2022[EB/OL]. (2022-05-30)[2023-12-15].
URL
|
| [37] |
Bressler NM, Beaulieu WT, Maguire MG, et al. Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in protocol T[J]. Am J Ophthalmol, 2018, 195:93-100.
|
| [38] |
Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema[J]. Ophthalmology, 2010, 117(6):1064-1077.
|
| [39] |
Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of Brolucizumab for neovascular age-related macular degeneration[J]. Ophthalmology, 2021, 128(1):89-99.
|
| [40] |
Liegl RG, Karcher H, Chetty-Mhlanga S, et al. The treatment patterns with brolucizumab in Germany (REALIZE) study: A retrospective cohort study based on longitudinal prescription data[J]. Ophthalmol Ther, 2023, 12(1):195-208.
|
| [41] |
Hirano T, Toriyama Y, Takahashi Y, et al. Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema[J]. Am J Ophthalmol Case Rep, 2022, 29:101788.
|
| [42] |
Justino LB, Justino GB, Graffunder FP, et al. Brolucizumab versus aflibercept in patients with diabetic macular edema: A meta-analysis of randomized controlled trials[J]. Clin Ophthalmol, 2024, 18:3679-3690.
|
| [43] |
Luu KT, Seal J, Green M, et al. Effect of anti-VEGF therapy on the disease progression of neovascular age-related macular degeneration: a systematic review and model-based meta-analysis[J]. J Clin Pharmacol, 2022, 62(5):594-608.
|
| [44] |
Kim J, Park MS, Cho BJ, et al. High-dose brolucizumab for refractory neovascular age-related macular degeneration resistant to standard-dose brolucizumab[J]. Ophthalmol Ther, 2024, 13(10):2789-2797.
|
| [45] |
Zarbin MA, MacCumber MW, Karcher H, et al. Real-world safety outcomes with brolucizumab in neovascular age-related macular degeneration: findings from the IRIS® registry[J]. Ophthalmol Ther, 2024, 13(5):1357-1368.
|
| [46] |
Igwe F, Lodha A, Ravindran A. Trends in the cumulative post-marketing reporting rates of retinal vasculitis and/or retinal vascular occlusion and associated vision loss with brolucizumab[J]. Ophthalmol Ther, 2023, 12(1):593-598.
|
| [47] |
邹杰，黄洁莹，孙劲楠，等.抗VEGF药物治疗新生血管性年龄相关性黄斑变性的药物经济学系统评价[J].中国医院药学杂志，2025,45(8):924-932.
|